Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	65.80B +14.5%
Revenue (ttm)	5.48B +35.9%
Net Income	949.28M +142.0%
EPS	0.84 +144.7%
Shares Out	1.11B
PE Ratio	70.52
Forward PE	47.85
Dividend	0.53 (0.89%)
Ex-Dividend Date	Sep 4, 2026

Volume	2,479,100
Open	56.99
Previous Close	58.99
Day's Range	56.99 - 60.43
52-Week Range	42.38 - 80.83
Beta	-0.19
Analysts	Strong Buy
Price Target	88.45 (+49.11%)
Earnings Date	Oct 28, 2026

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmac...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 5,597
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2025, SHE:002653's revenue was 4.39 billion, an increase of 17.91% compared to the previous year's 3.72 billion. Earnings were 259.58 million, a decrease of -34.36%.

Analyst Summary

According to 4 analysts, the average rating for 002653 stock is "Strong Buy." The 12-month stock price target is ¥88.45, which is an increase of 49.11% from the latest price.

Price Target

¥88.45

(49.11% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error